Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

B-Raf and Ha-ras mutations in chemically induced mouse liver tumors

Abstract

The mitogen-activated protein kinase signalling pathway is a central regulator of tumor growth, which is constitutively activated in chemically induced mouse liver tumors. In about 30–50% of cases this effect can be related to activation of the Ha-ras gene by point mutations, whereas in the remaining cases mutations may occur in other members within this pathway, such as Raf kinases. Recently, B-raf has been shown to be frequently mutated in human melanomas and certain other cancers, with a V599E amino-acid change representing the most predominant mutation type. We now screened 82 N-nitrosodiethylamine-induced liver tumors from C3H/He mice for mutations within the hotspot positions in the Ha-ras and B-raf genes. About 50% (39/82) of tumors showed Ha-ras codon 61 mutations and 16 tumors (20%) harbored mutations at codon 624 of the B-raf gene, which corresponds to codon 599 in human B-raf. None of the tumors was mutated in both Ha-ras and B-raf. The high prevalence of Ha-ras and B-raf mutations in mouse liver tumors is in striking contrast to human hepatocellular cancers which very infrequently harbor mutations in the two genes. These fundamental differences between the biology of liver tumors in mice and man may be of toxicological relevance.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Bauer-Hofmann R, Klimek F, Buchmann A, Müller O, Bannasch P and Schwarz M . (1992). Mol. Carcinogen., 6, 60–67.

  • Berg LM, Sanders R and Alderborn A . (2002). Expert Rev. Mol. Diagn., 2, 361–369.

  • Buchmann A, Bauer-Hofmann R, Mahr J, Drinkwater NR, Luz A and Schwarz M . (1991). Proc. Natl. Acad. Sci. USA, 88, 911–915.

  • Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R and McCubrey JA . (2003). Int. J. Oncol., 22, 469–480.

  • Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard Jones K, Maitland N, Chenevix Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA . (2002). Nature, 417, 949–954.

  • Downward J . (1998). Curr. Opin. Genet. Dev., 8, 49–54.

  • Downward J . (2003). Nat. Rev. Cancer, 3, 11–22.

  • Dragani TA, Manenti G, Colombo BM, Falvella FS, Gariboldi M, Pierotti MA and Della Porta G . (1991). Oncogene, 6, 333–338.

  • Erhardt P, Schremser EJ and Cooper GM . (1999). Mol. Cell. Biol., 19, 5308–5315.

  • Frey S, Buchmann A, Bursch W, Schulte-Hermann R and Schwarz M . (2000). Carcinogenesis, 21, 161–166.

  • Hagemann C and Rapp UR . (1999). Exp. Cell Res., 253, 34–46.

  • Hunter T . (1997). Cell, 88, 333–346.

  • Hüser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, Giblett S, Sun XM, Brown J, Marais R and Pritchard C . (2001). EMBO J., 20, 1940–1951.

  • Kalkuhl A, Troppmair J, Buchmann A, Stinchcombe S, Buenemann CL, Rapp UR, Kaestner K and Schwarz M . (1998). Hepatology, 27, 1081–1088.

  • Malumbres M and Barbacid M . (2003). Nat. Rev. Cancer, 3, 459–465.

  • Maronpot RR, Fox T, Malarkey DE and Goldsworthy TL . (1995). Toxicology, 101, 125–156.

  • Mercer KE and Pritchard CA . (2003). Biochim. Biophys. Acta, 1653, 25–40.

  • Mikula M, Schreiber M, Husak Z, Kucerova L, Rüth J, Wieser R, Zatloukal K, Beug H, Wagner EF and Baccarini M . (2001). EMBO J., 20, 1952–1962.

  • O'Neill E and Kolch W . (2004). Br. J. Cancer, 90, 283–288.

  • Schwarz M, Buchmann A, Stinchcombe S, Luebeck G, Moolgavkar S and Bock KW . (1995). Mutat. Res., 333, 69–79.

  • Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J and Wittekind C . (2003). Gut, 52, 706–712.

  • Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D and Marais R . (2004). Cell, 116, 855–867.

  • Wang H-G, Miyashita T, Takayama S, Sato T, Torigoe T, Krajewski S, Tanaka S, Hovey III L, Troppmair J, Rapp UR and Reed JC . (1994). Oncogene, 9, 2751–2756.

  • Wang HG, Rapp UR and Reed JC . (1996). Cell, 87, 629–638.

  • Xiao W and Oefner PJ . (2001). Hum. Mutat., 17, 439–474.

  • Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R and Leung SY . (2002). Cancer Res., 62, 6451–6455.

Download references

Acknowledgements

The excellent technical assistance of Mrs E Zabinsky and Mr M Niwar is acknowledged. We also thank Thomas Franck for his support in dHPLC analysis. This study was supported by the Deutsche Forschungsgemeinschaft (SCHW 329/3-1) to MS.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael Schwarz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jaworski, M., Buchmann, A., Bauer, P. et al. B-Raf and Ha-ras mutations in chemically induced mouse liver tumors. Oncogene 24, 1290–1295 (2005). https://doi.org/10.1038/sj.onc.1208265

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208265

Keywords

This article is cited by

Search

Quick links